{
  "id": 8031975,
  "title": "Five9 Inc stock hits 52-week high at 35.23 USD",
  "url": "https://urgent.news/2026/09/17/five9-inc-stock-hits-52-week-high-at-35-23-usd",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-17T13:49:10.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/five9-inc-stock-hits-52week-high-at-3523-usd-93CH-4905896"
  },
  "original_language": "en",
  "account": "Five9 Inc stock recently reached a noteworthy 52-week high of 35.23 USD, indicating a robust 27.58% growth over the past year. This surge is particularly significant as the stock has experienced a remarkable 113% increase over the past six months and a 70% gain year-to-date. These impressive statistics demonstrate strong investor confidence and illustrate Five9's growing influence in the competitive cloud-based contact center software market.\n\nInvestors analyzing Five9's performance have noted that the stock is currently trading below its Fair Value estimate, suggesting it may be undervalued. For those interested in a more detailed evaluation, a Pro Research Report is available, providing expert analysis on Five9 alongside insights on over 1,400 other US equities.\n\nThe company's recent second-quarter 2026 earnings exceeded Wall Street's expectations, delivering adjusted earnings of $0.70 per share, surpassing the forecast of $0.68. Additionally, Five9 reported revenue of $312.4 million, outpacing the estimated $306.43 million. The company's revenue for the quarter rose 10% year-over-year, totaling $312 million, which was higher than the high end of their guidance.\n\nSubscription revenue, in particular, demonstrated strong growth for the third consecutive quarter, increasing by 14% year-over-year. Five9's artificial intelligence (AI) revenue also showed impressive growth, rising 78% year-over-year to approximately $39 million. Notable analyst updates include FBN Securities initiating coverage on Five9 with an Outperform rating and a price target of $40. Truist Securities raised its price target to $40 from $35, maintaining a Buy rating, while DA Davidson increased its price target to $28 from $22, retaining a Neutral rating. Rosenblatt Securities also increased its price target to $32 from $29, maintaining a Buy rating based on Five9's strong second-quarter results. These developments highlight Five9's strategic focus on AI growth and its positive reception among financial experts.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Twist Bioscience stock hits 52-week high at 155.51 USD",
        "url": "https://urgent.news/2026/09/17/twist-bioscience-stock-hits-52-week-high-at-155-51-usd",
        "published": "2026-09-17T13:51:53.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}